We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -2.10 | -1.41% | 146.43 | 149.58 | 146.33 | 149.37 | 7,642,733 | 00:53:34 |
From Apr 2022 to Apr 2024
14:03 ET -- Johnson & Johnson is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The New Jersey-based drug company said its board has authorized the repurchase of up to $5 billion in stock and it doesn't expect to incur debt to fund the repurchases. J&J also reaffirmed its 2022 adjusted operational sales growth guidance of 6.5% to 7.5% and earnings per share at $10.65 to $10.75. "With our strong cash flow and lowest level of net debt in five years, we have the ability to invest in innovation, grow our dividend, execute strategic acquisitions, and take this action to deliver shareholder returns and drive long-term growth," said CEO Joaquin Duato. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
September 14, 2022 14:21 ET (18:21 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
